



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Subhashis Banerjee et al.

Serial No.: 10/623,065

ART UNIT: 1642

Filed: July 18, 2003

EXAMINER: David J. Blanchard

Entitled: TREATMENT OF CORONARY
DISORDERS USING TNF α
INHIBITORS

Attorney Docket No.: BBC-202

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

9/28/2005
Date


Daphne Miller

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Sir/Madam:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 for the above-identified application. Applicants makes the following publications of record in the above-identified application.

U.S. Patent Documents

Salfeld et al., July 18, 2000, U.S. Patent No. 6,090,382

Salfeld et al., July 10, 2001, U.S. Patent No. 6,258,562

Salfeld et al., January 21, 2003, U.S. Patent No. 6,509,015

Foreign Patent Documents

Kempeni et al., December 19, 2002, WO 02/100330

Fischkoff et al., January 15, 2004, WO 2004/004633

Krause et al., February 26, 2004, WO 2004/016286

Kaymakcalan et al., May 6, 2004, WO 2004/037205

Salfeld et al., August 14, 1997, WO 97/29131

Other Publications

Balbay *et al.* (2001) *Angiology*. 52:109

Belosjorow *et al.* *Am. J. Physiol. Heart Circ. Physiol.* 2003 Mar;284(3):H927-30. Epub 2002 Dec 05

Berk and Harris (1995) *Adv. Intern. Med.* 40:455-501

Bozkurt *et al.* *Circulation*. 2001 Feb 27;103(8):1044-7

Bult, H. (2000) *Trends in Pharmacological Sciences* 21:274-279

Burns *et al.* (2002) *J Am Coll Cardiol*. 39:30

Chung *et al.* *Circulation*. 2003 Jul 1;107(25):3133-40

Clagett *et al.* (1986) *J. Vasc. Surg.* 3:10-23

Clausell *et al.* *Br. Heart J.* 1995 Jun;73(6):534-9

Cleland *et al.* *Eur. J. Heart Fail.* 2001 Jun;3(3):381-7

Clowes *et al.* (1983) *Lab. Invest.* 49:208

Cusack *et al.* *J. Am. Coll. Cardiol.* 2002 Jun 19;39(12):1917-23

de Waard *et al.* (2002) *Arterioscler. Thromb. Vasc. Biol.* 22:1978

Deswal *et al.* *Circulation*. 1999 Jun 29;99(25):3224-6

Ferns *et al.* (1991) *Science* 253:1129

Fichtlscherer *et al.* *Circulation*. 2001 Dec 18;104(25):3023-5

Gurevitch *et al.* *J. Am. Coll. Cardiol.* 1997 Nov 15;30(6):1554-61

Halawa *et al.* *Pol. Arch. Med. Wewn.* 1999 Mar;101(3):197-203

Herskowitz *et al.* *Am. J. Pathol.* 1995 Feb;146(2):419-28

Hirschl *et al.* *Eur. Heart J.* 1996 Dec;17(12):1852-9

Ioculano *et al.* *Pharmacol. Res.* 1995 May;31(5):281-8

Jackson *et al.* (2003) *Am Heart J* 145:875

Jacobs *et al.* *J. Mol. Cell. Cardiol.* 1999 Nov;31(11):1949-59

Javed *et al.* *Exp. Mol. Pathol.* 2002 Oct;73(2):104-11

Kumar and Lindner (1997) *Arterioscler. Thromb. Vasc. Biol.* 17:2238

Kumar, *et al.* (1997) *Circulation* 96(12):4333-4342

Kurrelmeyer *et al.* *PNAS USA* 2000 May 9;97(10):5456-61

Lentz SR *et al.* (2002) *Circulation* 106(7):842-6

Levine *et al.* *N. Engl. J. Med.* 1990 Jul 26;323(4):236-41

Li *et al.* *Am. Heart J.* 1999 Jun;137(6):1145-52

Libby *Circulation* 1995;91:2844-50

Lindner *et al.* (1993) *Circ Res.* 73:792

Lissoni *et al.* *Eur. J. Med.* 1992 Sep;1(5):277-80

Maekawa *et al.* *J. Am. Coll. Cardiol.* 2002 Apr 3;39(7):1229-35

Mendall *et al.* (1997) *Heart* 78(3):273

Meng *et al.* *Shock.* 2002 May;17(5):345-53

Nakamura, *et al.* *J. Cardiol.* 2003 Jan;41(1):41-2

Old, L. (1985) *Science* 230:630-632

Orrego, *et al.* (1999) *Cardiologia* 44(7):621

Pudil *et al.* *Clin. Chim. Acta.* 1999 Feb;280(1-2):127-34

Ridker *et al.* *Circulation.* 2000 May 9;101(18):2149-53

Shames *et al.* *Shock.* 2002 Feb;17(2):114-9

Smith *et al.* *Br. J. Dermatol.* 2001 Mar;144(3):597-600

Soran *et al.* *Br. J. Clin. Pharmacol.* 2001 Feb;51(2):191-2

Squadrito *et al.* *Eur. J. Pharmacol.* 1993 Jun 24;237(2-3):223-30

Sugano *et al.* (2002) *FASEB J* 16:1421

Sundell CL *et al.* (2003)305(3):1116-23

Tanaka *et al.* *Arterioscler. Thromb. Vasc. Biol.* 1996 Jan;16(1):12-8

Torre-Amione *et al.* *J. Am. Coll. Cardiol.* 1996 Apr;27(5):1201-6

Valgimigli *et al.* *Circulation.* 2003 Jan 21;107(2):264-70

Yamashita *et al.* *Br. J. Pharmacol.* 2000 Oct;131(3):415-22

Zhou *et al.* *Atherosclerosis.* 2002 Mar;161(1):153-9

Zimmerman *et al.* *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2002 Aug;283(2):R505-12

Moreland, *et al.* *J. Invest. Med.* (1996) Vol. 44, 235A


Form PTO-1449 listing each of these documents and photocopies of each document are enclosed herewith for the Examiner's convenience.

This paper is being mailed before the mailing of a first Office action after the filing of a request for continued examination filed under 37 CFR §1.114. Pursuant to 37 CFR §1.97(b)(4), no fee is required with this submission.

Applicant does not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Tara Seshadri", written in a cursive style.

Tara Seshadri, Ph.D.
Agent for Applicant
Registration No. 48,591
Abbott Bioresearch Center, Inc.
100 Research Drive
Worcester, MA 01605-4314
Telephone: (508) 688-8058
Telefax: (508) 688-8110

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	7
-------	---	----	---

Complete if Known

Application Number	10/623,065
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1642
Examiner Name	David J. Blanchard
Attorney Docket Number	BBC-202

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
		WO 02/100330	12-19-2002	Abbott Biotechnology Ltd.		
		WO 04/004633	01-15-2004	Abbott Biotechnology Ltd.		
		WO 04/016286	02-26-2004	Abbott Laboratories (Berm		
		WO 04/037205	05-06-2004	Abbott Biotechnology Ltd.		
		WO 97/29131	08-14-1997	BASF Aktiengesellschaft		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/623,065
				Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	2	of	7	Attorney Docket Number	BBC-202

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		BÁLBAY et al. "Circulating Interleúkin-1 Beta, Interleukin-6, Tumor Necrosis Factor-Alpha, and Soluble ICAM-1 in Patients with Chronic Stable Angina and Myocardinal Infarction" (2001) Angiology. 52:109		
		BELOSJOROW et al. "TNF- α antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits" (2003) Am. J. Physiol. Heart Circ. Physiol. Mar; 284(3):H927-930.		
		BERK, BC et al. "Restenosis After Percutaneous Transluminal Coronary Angioplasty: New Therapeutic Insights From Pathogenic Mechanisms" (1995) Adv. Intern. Med., 40:455-501		
		BOZKURT et al. "Results of Targeted Anti-Tumor Necrosis Factor Therapy with Etanercept (ENBREL) in Patients with Advanced Heart Failure" (2001 Feb 27), 103(8):1044-7		
		BULT, H. "Restenosis: a challenge for pharmacology" (2000) Trends in Pharmacological Sciences, 21:274-279		
		BURNS, et al. "The Relationships of Left Ventricular Ejection Fraction, End-Systolic Volume Index and Infarct Size to Six-Month Mortality After Hospital Discharge Following Myocardial Infarction Treated by Thrombolysis" (2002) J. Am Coll Cardiol. 39:30		
		CHUNG, et al. "Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor- α , in Patients with Moderate-to-Severe Heart Failure" (2003 Jul 1) Circulation, 107(25):3133-40		
		CLAGETT, et al. "Morphogenesis and clinicopathologic characteristics of recurrent carotid disease" (1986) J. Vasc. Surg. 3:10-23		
		CLAUSELL, et al. "Expression of tumour necrosis factor α and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy" (1995) Br. Heart J., 73(6):534-539		
		CLELAND, et al. "Clinical Trials Update: Capricorn, Copernicus, Miracle, Staf, Ritz-2, Recover and Renaissance and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001" (2001 Jun) Eur. J. Heart Fail. , 3(3):381-387		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/623,065
				Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	3	of	7	Attorney Docket Number	BBC-202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CLOWES, et al. "Mechanisms of Stenosis after Arterial Injury" (1983) Laboratory Investigation, 49:208	
		CUSACK, et al. "Systemic Inflammation in Unstable Angina Is the Result of Myocardial Necrosis" (2002 June 19) J. Am. Coll. Cardiol. 39(12):1917-1923	
		de WAARD, et al. "Plasminogen Activator Inhibitor 1 and Vitronectin Protect Against Stenosis in a Murine Carotid Artery Ligation Model" (2002) Arterioscler. Thromb. Vasc. Biol. 22:1978-1983.	
		DESWAL, et al. "Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure" (1999 Jun 29), Circulation, 99(25):3224-3226	
		FERNS, et al. "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF" (1991) Science 253:1129	
		FICHTLSCHERER, et al. "Tumor Necrosis Factor Antagonism With Etanercept Improves Systemic Endothelial Vasoreactivity in Patients with Advanced Heart Failure" (2001 Dec 18) Circulation 104(25):3023-3025	
		GUREVITCH, et al. "Anti-Tumor Necrosis Factor-Alpha Improves Myocardial Recovery After Ischemia and Reperfusion" (1997 Nov 15) J. Am Coll. Cardiol. 30(6):1554-1561	
		HALAWA, et al. "Tumor necrosis factor (TNF- α) and interleukin 6 (IL-6) plasma levels in patients with acute myocardial infarction" (1999 Mar) Pol. Arch. Med. Wewn. 101(3):197-203	
		HERSKOWITZ, et al. "Cytokine mRNA Expression in Postischemic/Reperfused Myocardium" (1995 Feb) A. J. Pathol. 146(2): 419-428	
		HIRSCHL, et al. "Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction" (1996 Dec) Eur. Heart J. 17(12):1852-1859	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/623,065
				Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	4	of	7	Attorney Docket Number	BBC-202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		IOCULANO, et al. "Tumour Necrosis Factor Mediates E-Selectin Production and Leukocyte Accumulation In Myocardial Ischaemia-Reperfusion Injury" (1995 May) Pharmacol. Res. 31(5):281-288	
		JACKSON, et al. "β-Blockers reduce the incidence of clinical restenosis: Prospective study of 4840 patients undergoing percutaneous coronary revascularization" (2003) Am Heart J. 145:875	
		JACOBS, et al. "Tumor Necrosis Factor-α at Acute Myocardial Infarction in Rats and Effects on Cardiac Fibroblasts" (1999 Nov) J. Mol. Cell. Cardiol. 31(11):1949-1959	
		JAVED, et al. "Tumor Necrosis Factor-α Antibody Eluting Stents Reduce Vascular Smooth Muscle Cell Proliferation in Saphenous Vein Organ Culture" (2002 Oct) Exp. Mol. Pathol. 73(2):104-111	
		KUMAR, A. AND LINDNER, V. "Remodeling with Neointima Formation in the Mouse Carotid Artery After Cessation of Blood Flow" (1997) Arterioscler. Thromb. Vasc. Biol. 17:2238	
		KUMAR, et al. "Remodeling and Neointimal Formation in the Carotid Artery of Normal and P-Selectin-Deficient Mice" (1997) Circulation 96(12):4333-4342	
		KURRELMAYER, et al. "Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction" (2000 May 9) PNAS USA 97(10):5456-5461	
		LENTZ, et al. "Anticoagulant Responses to Thrombin Are Enhanced During Regression of Atherosclerosis in Monkeys" (2002) Circulation 106(7):842-846	
		LEVINE, et al. "Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure" (1990 Jul 26) N. Engl. J. Med. 323(4):236-241	
		LI, et al. "Kinetics of tumor necrosis factor α in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor α in a acute myocardial infarction" (1999 Jun) Am Heart J. 137(6):1145-52	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/623,065
				Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	5	of	7	Attorney Docket Number	BBC-202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LIBBY, PETER, MD. "Molecular Bases of the Acute Coronary Syndromes" (1995) Circulation 91:2844-2850	
		LINDNER, et al. "Mouse Model of Arterial Injury" (1993) Circ Res. 73:792	
		LISSONI, et al. "Enhanced Secretion of Tumour Necrosis Factor in Patients with Myocardial Infarction" (1992 Sep) Eur. J. Med. 1(5):277-280	
		MAEKAWA, et al. "Improved Myocardial Ischemia/Reperfusion Injury in Mice Lacking Tumor Necrosis Factor- α " (2002 Apr 3) J. Am. coll. Cardiol. 39(7): 1229-1235	
		MENDALL, et al. "Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease" (1997) Heart 78(3):273-277	
		MENG, et al. "The Interaction Between HSP70 and TNF- α Expression: A Novel Mechanism For Protection of the Myocardium Against Post-Injury Depression" (2002 May) Shock 17(5):345-353	
		NAKAMURA, et al. "Induction of Left Ventricular Remodeling and Dysfunction in the Recipient Heart Following Donor Heart Myocardial Infarction: New Insights into the Pathological Role of Tumor Necrosis Factor- α From a Novel Heterotopic Transplant-Coronary Ligation Model" (2003 Jan) J. Cardiol. 41(1):41-42	
		OLD, LLOYD J. "Tumor Necrosis Factor (TNF) (1985) Science 230:630-632	
		ORREGO, et al. "Coronary angioplasty and coronary artery remodeling" (1999) Cardiologia 44(7):621-625	
		PUDIL, et al. "Cytokines and adhesion molecules in the course of acute myocardial infarction" (1999 Feb) Clin. Chim. Acta. 280(1-2):127-134	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/623,065
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1642
Examiner Name	David J. Blanchard
Attorney Docket Number	BBC-202

Sheet	6	of	7
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		RIDKER, et al. "Elevation of Tumor Necrosis Factor- α and Increased Risk of Recurrent Coronary Events After Myocardial Infarction" (2000 May) Circulation 101(18):2149-2153	
		SHAMES, et al. "Ischemia Alone Is Sufficient To Induce TNF- α mRNA and Peptide In The Myocardium" (2002 Feb) Shock 17(2):114-119	
		SMITH, K.J. AND SKELTON, H. "Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor- α receptor fusion protein" (2001 Mar) Br. J. Dermatol. 144(3):597-600	
		SORAN, et al. "The pharmacokinetics of etanercept in patients with heart failure" (2001 Feb) 51(2):191-192	
		SQUADRITO, et al. "Tumor necrosis factor involvement in myocardial ischaemia-reperfusion injury" (1993 Jun 24) Eur. J. Pharmacol. 237(2-3):223-30	
		SUGANO, et al. "In vivo gene transfer of soluble TNF- α receptor 1 alleviates myocardial infarction" (2002) FASEB J 16:1421	
		SUNDELL, et al. "AGI-1067: A Multifunctional Phenolic Antioxidant, Lipid Modulator, Anti-Inflammatory and Antiatherosclerotic Agent" (2003) The J of Pharmacology & Experimental Therapeutics 305(3):1116-1123	
		TANAKA, et al. "Proliferating Arterial Smooth Muscle Cells After Balloon Injury Express TNF- α but Not Interleukin-1 or Basic Fibroblast Growth Factor" (1996 Jan) Arterioscler. Thromb. Vasc. Biol. 15(1):12-18	
		TORRE-AMIONE, et al. "Proinflammatory Cytokine Levels in Patients with Depressed Left Ventricular Ejection Fraction: A Report From the Studies of Left Ventricular Dysfunction (SOLVD)" (1996 Apr) J. Am. Coll. Cardiol. 27(5):1201-1206	
		VALGIMIGLI, et al. "Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells" (2003 Jan) Circulation 107(2):264-270	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/623,065		
		Filing Date	July 18, 2003		
		First Named Inventor	S. Banerjee		
		Art Unit	1642		
		Examiner Name	David J. Blanchard		
Sheet	7	of	7	Attorney Docket Number	BBC-202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		YAMASHITA, et al. "The involvement of cytokins in the second window of ischaemic preconditioning" (2000 Oct) Br. J. Pharmacol 131(3):415-422	
		ZHOU, et al. "Effect of anti-tumor necrosis factor- α polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model" (2002 Mar) Atherosclerosis 161(1):153-159	
		ZIMMERMAN, et al. "Lack of TNF α attenuates intimal hyperplasia after mouse carotid artery injury" (2002 Aug) Am. J. Physiol. Regul. Integr. Comp. Physiol 283(2): R505-512	
		MORELAND, et al. "Double Blind Placebo Controlled Trial of Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fe) In Active Rheumatoid Arthritis" (1996) J. Invest. Med. 44:235A	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.